메뉴 건너뛰기




Volumn 30, Issue 12, 2012, Pages

Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

EID: 84862252300     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.9973     Document Type: Article
Times cited : (58)

References (35)
  • 1
    • 0034993741 scopus 로고    scopus 로고
    • Classes of c-KIT activating mutations: Proposed mechanisms of action and implications for disease classification and therapy
    • DOI 10.1016/S0145-2126(01)00028-5, PII S0145212601000285
    • Longley BJ, Reguera MJ, Ma Y: Classes of c-KIT activating mutations: Proposed mechanisms of action and implications for disease classification and therapy. Leuk Res 25:571-576, 2001 (Pubitemid 32506764)
    • (2001) Leukemia Research , vol.25 , Issue.7 , pp. 571-576
    • Longley, B.J.1    Reguera, M.J.2    Ma, Y.3
  • 5
    • 64249092051 scopus 로고    scopus 로고
    • Advanced mast cell disease: An Italian Hematological Multicenter experience
    • Pagano L, Valentini CG, Caira M, et al: Advanced mast cell disease: An Italian Hematological Multicenter experience. Int J Hematol 88:483-488, 2008
    • (2008) Int J Hematol , vol.88 , pp. 483-488
    • Pagano, L.1    Valentini, C.G.2    Caira, M.3
  • 6
    • 68649118339 scopus 로고    scopus 로고
    • Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis
    • Vega-Ruiz A, Cortes JE, Sever M, et al: Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res 33:1481-1484, 2009
    • (2009) Leuk Res , vol.33 , pp. 1481-1484
    • Vega-Ruiz, A.1    Cortes, J.E.2    Sever, M.3
  • 7
    • 79960629726 scopus 로고    scopus 로고
    • Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis
    • Wasag B, Niedoszytko M, Piskorz A, et al: Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis. Exp Hematol 39:859-865, 2011
    • (2011) Exp Hematol , vol.39 , pp. 859-865
    • Wasag, B.1    Niedoszytko, M.2    Piskorz, A.3
  • 8
    • 33947520803 scopus 로고    scopus 로고
    • Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation
    • DOI 10.1038/labinvest.3700524, PII 3700524
    • Nakagomi N, Hirota S: Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation. Lab Invest 87:365-371, 2007 (Pubitemid 46474567)
    • (2007) Laboratory Investigation , vol.87 , Issue.4 , pp. 365-371
    • Nakagomi, N.1    Hirota, S.2
  • 10
    • 1842579440 scopus 로고    scopus 로고
    • A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib
    • DOI 10.1182/blood-2003-11-3816
    • Akin C, Fumo G, Yavuz AS, et al: A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 103:3222-3225, 2004 (Pubitemid 38451702)
    • (2004) Blood , vol.103 , Issue.8 , pp. 3222-3225
    • Akin, C.1    Fumo, G.2    Yavuz, A.S.3    Lipsky, P.E.4    Neckers, L.5    Metcalfe, D.D.6
  • 12
    • 52649177664 scopus 로고    scopus 로고
    • Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation
    • Hoffmann KM, Moser A, Lohse P, et al: Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation. Blood 112:1655-1657, 2008
    • (2008) Blood , vol.112 , pp. 1655-1657
    • Hoffmann, K.M.1    Moser, A.2    Lohse, P.3
  • 13
    • 33747336609 scopus 로고    scopus 로고
    • Well-differentiated systemic mastocytosis: A new disease variant with mature mast cell phenotype and lack of codon 816 c-kit mutations
    • Akin C, Escribano L, Núñez R, et al: Well-differentiated systemic mastocytosis: A new disease variant with mature mast cell phenotype and lack of codon 816 c-kit mutations. J Allergy Clin Immunol 113:S327, 2004
    • (2004) J Allergy Clin Immunol , vol.113
    • Akin, C.1    Escribano, L.2    Núñez, R.3
  • 14
    • 77949268924 scopus 로고    scopus 로고
    • Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes
    • Teodosio C, García-Montero AC, Jara-Acevedo M, et al: Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. J Allergy Clin Immunol 125:719-726, 2010
    • (2010) J Allergy Clin Immunol , vol.125 , pp. 719-726
    • Teodosio, C.1    García-Montero, A.C.2    Jara-Acevedo, M.3
  • 15
    • 80052422183 scopus 로고    scopus 로고
    • Evaluation of the WHO criteria for the classification of patients with mastocytosis
    • Sánchez-Munoz L, Alvarez-Twose I, García-Montero AC, et al: Evaluation of the WHO criteria for the classification of patients with mastocytosis. Mod Pathol 24:1157-1168, 2011
    • (2011) Mod Pathol , vol.24 , pp. 1157-1168
    • Sánchez-Munoz, L.1    Alvarez-Twose, I.2    García-Montero, A.C.3
  • 17
    • 0035810142 scopus 로고    scopus 로고
    • Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
    • DOI 10.1056/NEJM200104053441402
    • Druker BJ, Sawyers CL, Kantarjian H, et al: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042, 2001 (Pubitemid 32267973)
    • (2001) New England Journal of Medicine , vol.344 , Issue.14 , pp. 1038-1042
    • Druker, B.J.1    Sawyers, C.L.2    Kantarjian, H.3    Resta, D.J.4    Reese, S.F.5    Ford, J.M.6    Capdeville, R.7    Talpaz, M.8
  • 19
    • 0035823530 scopus 로고    scopus 로고
    • Case report: Rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate
    • Schaller JL, Burkland GA: Case report: Rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. MedGenMed 3:9, 2001
    • (2001) MedGenMed , vol.3 , pp. 9
    • Schaller, J.L.1    Burkland, G.A.2
  • 20
    • 0036063077 scopus 로고    scopus 로고
    • Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate
    • DOI 10.1016/S0145-2126(02)00046-2, PII S0145212602000462
    • Ault P, Cortes J, Koller C, et al: Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res 26:881-884, 2002 (Pubitemid 34790218)
    • (2002) Leukemia Research , vol.26 , Issue.9 , pp. 881-884
    • Ault, P.1    Cortes, J.2    Koller, C.3    Kaled, E.S.4    Kantarjian, H.5
  • 22
    • 0038792233 scopus 로고    scopus 로고
    • Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness
    • Klion AD, Noel P, Akin C, et al: Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 101:4660-4666, 2003 (Pubitemid 36857718)
    • (2003) Blood , vol.101 , Issue.12 , pp. 4660-4666
    • Klion, A.D.1    Noel, P.2    Akin, C.3    Law, M.A.4    Gilliland, D.G.5    Cools, J.6    Metcalfe, D.D.7    Nutman, T.B.8
  • 26
    • 0036493872 scopus 로고    scopus 로고
    • The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wildtype kinases and those with regulatory-type mutations
    • Ma Y, Zeng S, Metcalfe DD, et al: The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wildtype kinases and those with regulatory-type mutations. Blood 99:1741-1744, 2002
    • (2002) Blood , vol.99 , pp. 1741-1744
    • Ma, Y.1    Zeng, S.2    Metcalfe, D.D.3
  • 27
    • 2942542387 scopus 로고    scopus 로고
    • Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase
    • Mol CD, Dougan DR, Schneider TR, et al: Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 279:31655-31663, 2004
    • (2004) J Biol Chem , vol.279 , pp. 31655-31663
    • Mol, C.D.1    Dougan, D.R.2    Schneider, T.R.3
  • 28
    • 0038731316 scopus 로고    scopus 로고
    • Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant
    • Frost MJ, Ferrao PT, Hughes TP, et al: Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 1:1115-1124, 2002
    • (2002) Mol Cancer Ther , vol.1 , pp. 1115-1124
    • Frost, M.J.1    Ferrao, P.T.2    Hughes, T.P.3
  • 30
    • 79955998389 scopus 로고    scopus 로고
    • A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib
    • Mital A, Piskorz A, Lewandowski K, et al: A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib. Eur J Haematol 86:531-535, 2011
    • (2011) Eur J Haematol , vol.86 , pp. 531-535
    • Mital, A.1    Piskorz, A.2    Lewandowski, K.3
  • 31
    • 77951066096 scopus 로고    scopus 로고
    • A critical reappraisal of treatment response criteria in systemic mastocytosis and a proposal for revisions
    • Pardanani A, Tefferi A: A critical reappraisal of treatment response criteria in systemic mastocytosis and a proposal for revisions. Eur J Haematol 84:371-378, 2010
    • (2010) Eur J Haematol , vol.84 , pp. 371-378
    • Pardanani, A.1    Tefferi, A.2
  • 32
    • 79958788970 scopus 로고    scopus 로고
    • Imatinib mesylate for aggressive systemic mastocytosis with long bone osteolysis
    • Jung AG, Horny HP, Sotlar K, et al: Imatinib mesylate for aggressive systemic mastocytosis with long bone osteolysis. J Am Acad Dermatol 65:224-226, 2011
    • (2011) J Am Acad Dermatol , vol.65 , pp. 224-226
    • Jung, A.G.1    Horny, H.P.2    Sotlar, K.3
  • 33
    • 69349102308 scopus 로고    scopus 로고
    • Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients
    • Escribano L, Alvarez-Twose I, Sánchez-Munoz L, et al: Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol 124:514-521, 2009
    • (2009) J Allergy Clin Immunol , vol.124 , pp. 514-521
    • Escribano, L.1    Alvarez-Twose, I.2    Sánchez-Munoz, L.3
  • 34
    • 76749089140 scopus 로고    scopus 로고
    • Systemic mastocytosis in adults: A review on prognosis and treatment based on 342 Mayo Clinic patients and current literature
    • Pardanani A, Tefferi A: Systemic mastocytosis in adults: A review on prognosis and treatment based on 342 Mayo Clinic patients and current literature. Curr Opin Hematol 17:125-132, 2010
    • (2010) Curr Opin Hematol , vol.17 , pp. 125-132
    • Pardanani, A.1    Tefferi, A.2
  • 35
    • 0018411931 scopus 로고
    • Production and life span of cutaneous mast cells in young rats
    • Kiernan JA: Production and life span of cutaneous mast cells in young rats. J Anat 128:225-238, 1979
    • (1979) J Anat , vol.128 , pp. 225-238
    • Kiernan, J.A.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.